Andrew E. Hendifar, MD
Medical Oncologist
Asbestosis Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Dr. Andrew Hendifar is a specialist in medical oncology based in Los Angeles, California and he is working in collaboration with many regional hospitals, such as Cedars-Sinai Medical Center and Keck Medical Center of USC. He graduated from Tulane University School of Medicine where he got his medical degree. He completed his residency program in internal medicine at the University of Southern California - LAC+USC Medical Center. He did two fellowships, one in medical oncology and one in hematology, both of them at University of Southern California - LAC+USC Medical Center. The doctor is board certified in hematology, internal medicine, and medical oncology and he has been practicing for more than 20 years.
Tulane University School of Medicine
Medical School
University of Southern California - LAC+USC Medical Center
Residency
University of Southern California - LAC+USC Medical Center
Fellowship
American Board of Internal Medicine
American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Oncology
Keck Hospital of USC - Medical Center
Languages: English/Spanish
(323) 442-8500
1500 San Pablo St
Read MoreProvidence Saint John's Health Center
Languages: English/Spanish
(310) 829-5511
2121 Santa Monica Boulevard
Santa Monica, California 90404
Ronald Reagan UCLA Medical Center
Languages: English/Spanish
(310) 825-9111
757 Westwood Plaza
Read MoreImpact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy.
Osipov, A.,Naziri, J.,Hendifar, A.,Dhall, D.,Rutgers, J. K.,Chopra, S.,Li, Q.,Tighiouart, M.,Annamalai, A.,Nissen, N. N.,Tuli, R.; J Gastrointest Oncol. 2016 Apr 02.
See more >>Meta-analyses of treatment standards for pancreatic cancer.
Gong, J.,Tuli, R.,Shinde, A.,Hendifar, A. E.; Mol Clin Oncol. 1900 Jan 01.
See more >>Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
Hendifar, A.,Tan, C. R.,Annamalai, A.,Tuli, R.; Expert Rev Anticancer Ther. 2014 Jun 06.
See more >>American Society of Clinical Oncology